Navigation Links
Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product
Date:1/5/2012

BRIDGEWATER, N.J., Jan. 5, 2012 /PRNewswire/ -- Sanofi US today announced that the U. S. District Court in Massachusetts granted the company a preliminary injunction against a Synvisc-One® (hylan G-F 20) competitor product developed by Seikagaku Corporation. The ruling allows for a restricted launch of Seikagaku's product prior to a scheduled trial date in April, and prohibits Seikagaku from selling their product below the current average sales price for Synvisc-One.

(Logo:  http://photos.prnewswire.com/prnh/20110616/NY20158LOGO )

In its recent ruling, the Court found that Seikagaku was not likely to prevail at trial, which will focus on U.S. Patent 7,931,030.

"We are pleased that the Court recognized the strength of our '030 patent, which protects Genzyme's Synvisc-One® franchise," said Alison Lawton, Senior Vice President and General Manager of Sanofi's Biosurgery business. "We are also pleased that the Court took decisive steps to protect the market position that Genzyme earned through its research and development and product innovation."

Synvisc-One® has been the only single-injection viscosupplement for the treatment of osteoarthritis (OA) knee pain on the U.S. market since it was launched in the first quarter of 2009.  The market for such treatments is large, growing and underpenetrated; of the estimated 9 million eligible OA patients in the United States, only about 14 percent are currently treated with viscosupplements.

Sanofi's Biosurgery business, which markets a variety of products globally in the areas of osteoarthritis, postoperative adhesion prevention, and cell therapy, is focused on transforming disease management through innovative medical interventions.  It became part of Sanofi following the company's acquisition of Genzyme Corporation
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... , Spanje, July 4, 2015 ... harsmicrosferen aan eerstelijns chemotherapie voor patiënten met ... (mCRC) verlengt de progressievrije overleving in dat ... gemetastaseerde colorectale kanker (mCRC) die alleen binnen ... gezien in progressievrije overleving (PFS) in de ...
(Date:7/3/2015)... , July 4, 2015 A ... of hypertension, diabetes and thyroid disorders in Central and ... educational platforms and a major conference dedicated to these ... Manage Diabetes Online , Manage Hypertension Online ... developed and operated by EXCEMED - combine ...
(Date:7/3/2015)... A global continuing medical education ... thyroid disorders in Latin America ... dedicated to these diseases.      (Logo: http://photos.prnewswire.com/prnh/20150630/227033) ... Manage Hypertension Online and Manage Thyroid Online ... - combine the world,s top expertise with dynamic ...
Breaking Medicine Technology:Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Combating Three Major Chronic Diseases in Central and South-East Asia With Medical Education 2Combating Three Major Chronic Diseases in Latin America With Medical Education 2
... LONDON, March 19, 2007-AstraZeneca today announced that ... results from the ARISE (Aggressive Reduction of ... which studied,AGI-1067, an investigational anti-atherosclerotic agent with,antioxidant ... disease (CAD). ,The ARISE trial did not ...
... /PRNewswire-FirstCall/ --,Nuvelo, Inc. today announced that clinical data ... MACE)/TIMI 32 Phase,2 trial looking at recombinant nematode ... coronary syndromes,(NSTE-ACS) will be presented in a V-poster ... Session taking place in New,Orleans, LA, March 24-27, ...
Cached Medicine Technology:Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 3
(Date:7/6/2015)... ... July 06, 2015 , ... ... Spa industries, announces the return of its complimentary educational webinar series ... medical business leaders creates success for their clients through targeted marketing, sales, digital ...
(Date:7/6/2015)... Beach, Virginia (PRWEB) , ... July 06, 2015 ... ... States choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction ... country. For a particular demographic, however, fat reduction has become more than a ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to announce ... Teaching Award on behalf of the department of Family Practice. , “This award is ... be practicing in. The technology is changing so rapidly and we are also developing ...
(Date:7/6/2015)... ... July 06, 2015 , ... doTERRA, the leading global ... executive management team. Most recently, Jowers held the position as Director of the Hinckley ... After spending a decade building the institute, Jowers states that he was ready for ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... redesigned site allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with ... survived the same cancer. , “Receiving a cancer diagnosis is often the most ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... UPTON, NY - A new study by scientists at the ... Norway suggests that the benefits of moderately increased exposure to ... against the lethal effects of many forms of cancer and ... cancer in populations deficient in vitamin D. The study will ...
... activate abnormally in malignant cells , , MONDAY, Jan. 7 (HealthDay ... genes that play a role in cell division, and ... of those genes show an abnormal pattern of activation in ... issue of the Proceedings of the National Academy of ...
... University Center for Clinical and Translational Science (CCTS) has ... Eight Rockefeller researchers will each receive $25,000 from the ... if successful, might lead to clinical trials. The CCTS ... established through funds from a Clinical and Translational Science ...
... caused by aging, can also be caused by pesticides ... that trichloroethylene (TCE) is a risk factor for parkinsonism, ... Parkinsons disease. TCE is a chemical widely used in ... water and soil due to runoff from manufacturing sites ...
... experts are split on the need for supplements , , MONDAY, ... D -- sourced through sunlight, some foods and supplements ... such as heart attack and stroke, U.S. researchers report. , ... Heart Study included 1,739 people, average age 59, living in ...
... suffering from a form of asphyxia at birth have ... a lifetime of debilitating and costly health complications, according ... , The findings, which appear today in the January ... technique, that better availability and placement of CoolCaps within ...
Cached Medicine News:Health News:More sun exposure may be good for some people 2Health News:More sun exposure may be good for some people 3Health News:Team Finds 118 Genes That Might Play Role in Cancer 2Health News:Rockefeller University's Center for Clinical and Translational Science funds pilot studies 2Health News:Trichloroethylene is a risk factor for parkinsonism 2Health News:Trichloroethylene is a risk factor for parkinsonism 3Health News:Low Vitamin D Linked to Heart Risk 2Health News:Low Vitamin D Linked to Heart Risk 3Health News:Better access to cool caps improves outcomes, lowers cost of treating asphyxia in newborns 2
... an enzymatic cleanser for automated and semi-automated ... 475ml bottle has a flip-top spout for ... that require manual addition of an enzyme ... of this product. The shelf life of ...
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
... is a nucleated red blood cell (nRBC) control ... Coulter LH 750/LH 755 hematology analyzer in its ... for the Coulter LH 750/LH 755. nRBC-Chex for ... cap-pierceable vials. nRBC-Chex for LH has a 75-day ...
Medicine Products: